{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-258490","form_type":"8-K","ticker":null,"cik":"0001538210","company_name":"NexImmune, Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.424231+00:00","generated_at":"2026-06-09T21:48:47.243245+00:00","sec_items":["5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NexImmune announces 1-for-25 reverse stock split effective Oct 18, 2023 to regain Nasdaq compliance","bullets":["Reverse stock split at 1-for-25 ratio effective after market close on Oct 18, 2023.","Shares outstanding reduced from ~26.5M to ~1.06M; authorized shares unchanged at 100M.","Stockholders approved split at special meeting on Oct 17, 2023 (13.8M for, 344K against).","Split is intended to regain minimum bid price compliance on Nasdaq Capital Market.","Fractional shares cashed out at closing price on Oct 18; CUSIP changes to 65344D 208."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-258490","json":"https://secwatch.observer/filing/0001193125-23-258490.json","markdown":"https://secwatch.observer/filing/0001193125-23-258490.md","text":"https://secwatch.observer/filing/0001193125-23-258490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523258490/0001193125-23-258490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523258490/d331798d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:48:47.243245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4da9ea6f5a4625a159386d86768ff824e529d6e9","claim":"NexImmune, Inc.: Reverse stock split at 1-for-25 ratio, effective after close of trading on October 18, 2023 (effective 2023-10-18).","evidence_excerpt":"On October 18, 2023, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company’s common stock, at a ratio of 1-for-25 (the “Reverse Stock Split”). The Reverse Stock Split was effective at 5 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on October 18, 2023 (the “Effective Time”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523258490/0001193125-23-258490-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-18"}],"fact_type":"governance_change"},{"claim_id":"32747e3d516359f546b6d19651f9b8e82109456e","claim":"NexImmune, Inc. shareholders approved Approval of adjournment of the special meeting to solicit additional proxies if necessary. at the 2023-10-17 meeting.","evidence_excerpt":"Votes For Votes Against Votes Abstained 13,899,330 286,293 88,853","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523258490/0001193125-23-258490-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-17"}],"fact_type":"shareholder_vote"},{"claim_id":"e6fc2da1955d40be7b49e7b83fb3b6a18684410e","claim":"NexImmune, Inc. shareholders approved Approval of amendment to certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-4 and not more than 1-for-50, with exact ratio set by board. at the 2023-10-17 meeting.","evidence_excerpt":"Votes For Votes Against Votes Abstained 13,838,206 344,220 92,050","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523258490/0001193125-23-258490-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}